TY - JOUR
T1 - Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency
AU - Busse, Paula Jane
AU - Razvi, Samiya
AU - Cunningham-Rundles, Charlotte
N1 - Funding Information:
Supported by the Immune Deficiency Foundation (Towson, Md), National Institutes of Health grants AI46732 and AI48693, and Food and Drug Administration grant 001679.
PY - 2002
Y1 - 2002
N2 - Background: Common variable immunodeficiency (CVID) is a primary immune disorder characterized by antibody deficiency and a decrease in serum IgG and IgA, IgM, or both levels at least 2 SDs below the mean for age and not attributed to other known immunologic disorders. These patients often present with frequent and severe episodes of pneumonia before diagnosis. The standard treatment, intravenous immunoglobulin (IVIG), has been available for the past 20 years. No large-scale study has compared the incidence of pneumonia in these patients before and after IVIG treatment. Objective: The aim of this study was to document the effectiveness of intravenous immunoglobulin treatment on the incidence of pneumonia in patients with CVID. Methods: We performed chart reviews and interviews of patients with laboratory-confirmed CVID seen at our clinical center. The number of episodes of pneumonia was documented before and after treatment with immunoglobulin replacement therapy. Results: The histories of 50 patients were reviewed (mean current age, 42 ± 16.3 years; age range, 10-78 years; 20 male and 30 female patients). Forty-two (84%) of the 50 patients with CVID had pneumonia at least once before receiving immunoglobulin treatment, and 11 of 42 of these patients had multiple episodes. After treatment with gamma globulin over a mean period of 6.6 ± 5.2 years (range, <1-20 years), the number of patients experiencing pneumonia significantly decreased to 11 (22%) of 50. In most cases these patients had pneumonia in the first year of immunoglobulin treatment. Conclusion: The treatment of CVID with IVIG significantly reduces the incidence of pneumonia.
AB - Background: Common variable immunodeficiency (CVID) is a primary immune disorder characterized by antibody deficiency and a decrease in serum IgG and IgA, IgM, or both levels at least 2 SDs below the mean for age and not attributed to other known immunologic disorders. These patients often present with frequent and severe episodes of pneumonia before diagnosis. The standard treatment, intravenous immunoglobulin (IVIG), has been available for the past 20 years. No large-scale study has compared the incidence of pneumonia in these patients before and after IVIG treatment. Objective: The aim of this study was to document the effectiveness of intravenous immunoglobulin treatment on the incidence of pneumonia in patients with CVID. Methods: We performed chart reviews and interviews of patients with laboratory-confirmed CVID seen at our clinical center. The number of episodes of pneumonia was documented before and after treatment with immunoglobulin replacement therapy. Results: The histories of 50 patients were reviewed (mean current age, 42 ± 16.3 years; age range, 10-78 years; 20 male and 30 female patients). Forty-two (84%) of the 50 patients with CVID had pneumonia at least once before receiving immunoglobulin treatment, and 11 of 42 of these patients had multiple episodes. After treatment with gamma globulin over a mean period of 6.6 ± 5.2 years (range, <1-20 years), the number of patients experiencing pneumonia significantly decreased to 11 (22%) of 50. In most cases these patients had pneumonia in the first year of immunoglobulin treatment. Conclusion: The treatment of CVID with IVIG significantly reduces the incidence of pneumonia.
KW - Common variable immunodeficiency
KW - Efficacy
KW - Gamma globulin treatment
KW - Immunoglobulin
KW - Infection
KW - Pneumonia
KW - Prevention
UR - http://www.scopus.com/inward/record.url?scp=0036286074&partnerID=8YFLogxK
U2 - 10.1067/mai.2002.124999
DO - 10.1067/mai.2002.124999
M3 - Article
C2 - 12063531
AN - SCOPUS:0036286074
SN - 0091-6749
VL - 109
SP - 1001
EP - 1004
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -